Genmab — Juli 2018
-
"If daratumumab and CyBorD works better than CyBorD alone, we have a new standard of therapy for patients with light chain amyloidosis. In addition, the study is designed to allow patients to have their blood stem cells collected after 6 months of treatment"
. -
Tak for link GB.
-
den bed jeg også mærke i Helge 15.45 + "... 2 dozen patients were treated in the ramp-in, there was no safety problems with the subcutaneous daratumumab, and all of the 2 dozen patients received daratumumab with CyBorD.".
-
5/7 15:46
af gentogen
It is estimated that there are 12,000 adults in the United States currently living with AL amyloidosis. (Blood Cancer Journalvolume 8, Article number: 44 (2018) -
har tidligere læst her at markedet for amyloidosis har en størrelses på ca. 20% af MM markedet
-
noget kunne tyde på at dara virker endnu bedre i amyloisosis end i MM
-
Solsen. Resultater september. 18 . Men dog kun 18 patienter. If clinical trial. https://www.clinicaltrials.gov/ct2/show/NCT02955810?term=Dara%2BCyBorD&cond=MM&rank=1
-
-
new country, Panama - Aprueban nuevo tratamiento para el Mieloma Múltiple en Panamá - https://www.tvn-2.com/nacionales/salud/Aprueban-tratamiento-Mieloma-Multiple-Panama_0_5079991985.html
-
God morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind